gynaecological cancers - Oxford Journals - Oxford University Press

18 downloads 0 Views 37KB Size Report
2Cancer Research UK & UCL Cancer Trials Centre, University College London, ... University Press on behalf of the European Society for Medical Oncology.
Annals of Oncology 25 (Supplement 4): iv305–iv326, 2014 doi:10.1093/annonc/mdu338.54

gynaecological cancers 930P

A RETROSPECTIVE SINGLE INSTITUTION STUDY EVALUATING CLINICAL OUTCOME AND PROGNOSTIC MARKERS FOR ENDOMETRIAL AND OVARIAN CARCINOSARCOMAS (CS)

U.S. Asghar1, G. Imseeh1, A.A. Kirkwood2, M. Widschwendter3, A. Olaitan3, N. Macdonald3, T. Mould3, M. McCormack3, A. Mitra3, J.A. Ledermann4, R. Arora5, R. Kristeleit6 1 Clinical Research Unit, University College London Hospital, London, UK 2 Cancer Research UK & UCL Cancer Trials Centre, University College London, London, UK 3 Gynae-oncology Unit, University College London Hospital, London, UK 4 Cancer Research UK and UCL Cancer Trials Centre, University College London Cancer Institute, London, UK 5 Pathology, University College London Hospital, London, UK 6 UCLH Dept. of Oncology, UCL - University College London Cancer Institute, London, UK

Table: 930P Analysis for OS according to baseline characteristics

Original Tumour site Endometrial Ovarian FIGO Stage I/II III/IV Epithelial type Poorly/un-differentiated Other Cancer History No Yes Cancer FHx No Yes

OS #events/n

HR(95% CI)

p-value

33/72 6/10 10/37 22/33 15/39 16/31

1.0 1.33 (0.56 -3.17) 1.0 3.22 (1.52, 6.82) 1.0 1.55 (0.75,3.18)

0.5 0.001 0.23

22/56 10/18 26/56 7/15

1.00 1.23 (0.59, 2.55) 1.00 1.08 (0.47, 2.49)

0.58 0.86

All ovarian CS patients had surgical resection (SR), 90% completed 6 cycles of postoperative carboplatin/paclitaxel chemotherapy (CT) with 20% complete responses (CR) and 40% partial responses (PR). 88% of endometrial CS patients were treated with SR, CT +/- RT. The response rates (RR) after CT were 70% CR and 9% PR. Neither the epithelial subtypes, nor the presence of a heterologous component showed statistically significant difference for OS. Conclusions: Clinical outcome for ovarian (12%) vs. endometrial CS were comparable in regards to OS. FIGO stage was the only statistically significant prognostic factor. There was a trend for worse OS in CS with poorly/un- differentiated adenocarcinoma and/or absence of heterologous components although statistically not significant in this cohort. This warrants further clinical evaluation in a larger study. Disclosure: All authors have declared no conflicts of interest.

abstracts

Aim: To assess whether: (1) clinical outcomes for ovarian vs. endometrial CS were comparable (2) the epithelial histological subtype or presence of heterologous elements in the mesenchymal component impacted overall survival (OS) (3) a personal or family history (FHx) of cancer was associated with OS. Methods: Women treated at University College London Hospital Gynae-oncology Unit between April 2002 – 2011 were identified using electronic records. Patient clinical data and full histological reports were collected retrospectively from the medical records.

Results: 82 patients (72 endometrial; 10 ovarian) with a median age of 67 years were identified. 22% had a prior cancer history and 3.6% had previously received abdominal/pelvic radiotherapy (RT). Median OS was 26.7 months.

© European Society for Medical Oncology 2014. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: [email protected].